Michael H. Criqui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael H. Criqui has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- Matthew A. Allison
University of California San Diego
17 shared publications - Mary McGrae McDermott
Northwestern University Feinberg School of Medicine
10 shared publications Julie O. Denenberg
Department of Family Medicine and Public Health, UCSD, La Jolla, CA, USA
9 shared publications- Luigi Ferrucci
Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, USA
9 shared publications Robyn L. McClelland
Department of Biostatistics, University of Washington, Seattle (R.L.M.).
7 shared publications- Jack M. Guralnik
University of Maryland School of Medicine
6 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (11) , e020112
Development and Validation of a Coronary Artery Calcium Volume and Density Score
BACKGROUND: Coronary artery calcium (CAC) scoring is a useful tool for coronary heart disease (CHD) risk prediction. The current standard method, the Agatston score, weights plaque area upward by density. However, higher density is inversely associated with CHD. We aimed to develop and validate a CAC score accounting for the inverse association of density with CHD, and the nonlinear association between CAC volume and density in a prospective cohort study. METHODS: A CAC volume and density score was developed, which adjusts CAC volume for density based on whether the volume level was 0 and follow-up for CHD events. Score performance for CHD risk prediction was compared with the pooled cohort equations and the Agatston score using Cox proportional hazards models and Harrell C -index and continuous and categorical net reclassification improvement. Analyses were also stratified by Agatston score, age, sex, race/ethnicity, and statin use. Finally, performance was evaluated in 4 longitudinal cohorts for external validation. RESULTS: The MESA cohort included 3360 individuals. CAC volume and density score improved the C -index for CHD to a greater degree over the pooled cohort equation (0.699 [95% CI, 0.675–0.723]) compared with the Agatston score (0.687 [95% CI, 0.663–0.711]) and resulted in greater continuous net reclassification improvement (0.54 [95% CI, 0.43–0.64]) compared with the Agatston score (0.45 [95% CI, 0.34–0.56]) when added to the pooled cohort equation. The greatest improvement in risk prediction was in those with lower burden of CAC (Agatston <300). Consistent results were seen in stratified analyses and external validation cohorts. CONCLUSIONS: The CAC volume and density score, which adjusts CAC volume downward for higher density, and can be calculated from existing CAC reports, significantly improves risk discrimination and reclassification compared with the Agatston score.
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (11) , e020112
Development and Validation of a Coronary Artery Calcium Volume and Density Score
BACKGROUND: Coronary artery calcium (CAC) scoring is a useful tool for coronary heart disease (CHD) risk prediction. The current standard method, the Agatston score, weights plaque area upward by density. However, higher density is inversely associated with CHD. We aimed to develop and validate a CAC score accounting for the inverse association of density with CHD, and the nonlinear association between CAC volume and density in a prospective cohort study. METHODS: A CAC volume and density score was developed, which adjusts CAC volume for density based on whether the volume level was 0 and follow-up for CHD events. Score performance for CHD risk prediction was compared with the pooled cohort equations and the Agatston score using Cox proportional hazards models and Harrell C -index and continuous and categorical net reclassification improvement. Analyses were also stratified by Agatston score, age, sex, race/ethnicity, and statin use. Finally, performance was evaluated in 4 longitudinal cohorts for external validation. RESULTS: The MESA cohort included 3360 individuals. CAC volume and density score improved the C -index for CHD to a greater degree over the pooled cohort equation (0.699 [95% CI, 0.675–0.723]) compared with the Agatston score (0.687 [95% CI, 0.663–0.711]) and resulted in greater continuous net reclassification improvement (0.54 [95% CI, 0.43–0.64]) compared with the Agatston score (0.45 [95% CI, 0.34–0.56]) when added to the pooled cohort equation. The greatest improvement in risk prediction was in those with lower burden of CAC (Agatston <300). Consistent results were seen in stratified analyses and external validation cohorts. CONCLUSIONS: The CAC volume and density score, which adjusts CAC volume downward for higher density, and can be calculated from existing CAC reports, significantly improves risk discrimination and reclassification compared with the Agatston score.
- Open Access
- 5 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (18) , e040058
Duration of Supervised Exercise Necessary for Meaningful Improvement in Peripheral Artery Disease
Background: Supervised treadmill exercise improves walking performance in people with lower extremity peripheral artery disease, but benefits are not immediate. This study identified the time course of attaining meaningful improvement in 6‐minute walk distance and patient‐reported outcome measures during a 6‐month supervised exercise intervention in people with peripheral artery disease. Methods: Participants with peripheral artery disease were randomized to supervised treadmill exercise 3 time weekly or a nonexercise control group for 6 months. Six‐minute walk distance (large clinically important difference: 20 meters) and the Walking Impairment Questionnaire distance score (0–100 scale, 100 is best, clinically important difference: 5 points) were measured at the 6‐week, 12‐week, and 26‐week follow‐up using a mixed‐effects model for repeated measures. Results: Of 210 randomized participants (mean age, 67.0±8.6 years, 82 [39%] women, 141 [66%] Black), 200 (95%) completed at least 1 follow‐up visit. Compared with controls, supervised exercise significantly improved 6‐minute walk distance by 13.0 m ( P =0.049) at the 6‐week, 31.8 m ( P P P =0.37) at the 6‐week, +6.59 ( P =0.049) at the 12‐week, and +2.37 ( P =0.49) at the 26‐week follow‐up. Conclusions: In people with peripheral artery disease, >6 weeks of supervised treadmill exercise was necessary to attain a large meaningful gain in 6‐minute walk, and large meaningful gains were measurable by week 12 of supervised exercise. Meaningful improvement in participant reported walking ability was first observed at the 12‐week follow‐up, but this statistically significant benefit was gone by the 26‐week follow‐up. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01408901.
- 5 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (18) , e040058
Open AccessDuration of Supervised Exercise Necessary for Meaningful Improvement in Peripheral Artery Disease
Background: Supervised treadmill exercise improves walking performance in people with lower extremity peripheral artery disease, but benefits are not immediate. This study identified the time course of attaining meaningful improvement in 6‐minute walk distance and patient‐reported outcome measures during a 6‐month supervised exercise intervention in people with peripheral artery disease. Methods: Participants with peripheral artery disease were randomized to supervised treadmill exercise 3 time weekly or a nonexercise control group for 6 months. Six‐minute walk distance (large clinically important difference: 20 meters) and the Walking Impairment Questionnaire distance score (0–100 scale, 100 is best, clinically important difference: 5 points) were measured at the 6‐week, 12‐week, and 26‐week follow‐up using a mixed‐effects model for repeated measures. Results: Of 210 randomized participants (mean age, 67.0±8.6 years, 82 [39%] women, 141 [66%] Black), 200 (95%) completed at least 1 follow‐up visit. Compared with controls, supervised exercise significantly improved 6‐minute walk distance by 13.0 m ( P =0.049) at the 6‐week, 31.8 m ( P P P =0.37) at the 6‐week, +6.59 ( P =0.049) at the 12‐week, and +2.37 ( P =0.49) at the 26‐week follow‐up. Conclusions: In people with peripheral artery disease, >6 weeks of supervised treadmill exercise was necessary to attain a large meaningful gain in 6‐minute walk, and large meaningful gains were measurable by week 12 of supervised exercise. Meaningful improvement in participant reported walking ability was first observed at the 12‐week follow‐up, but this statistically significant benefit was gone by the 26‐week follow‐up. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01408901.
- 1 November 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (11) , 2347-2359
Associations Between Flavonoid Intake and Subclinical Atherosclerosis: The Multi-Ethnic Study of Atherosclerosis
BACKGROUND: Flavonoids may play a role in mitigating atherosclerotic cardiovascular diseases, with evidence suggesting effects may differ between vascular beds. Studies examining associations with subclinical markers of atherosclerosis between subpopulations with different underlying risks of atherosclerosis are lacking. METHODS: Among 5599 participants from the MESA (Multi-Ethnic Study of Atherosclerosis), associations between dietary flavonoid intakes (estimated from a food frequency questionnaire) and subclinical measures of atherosclerosis (ankle-brachial index, carotid plaques and intima-media thickness, and coronary artery calcification) were examined using repeated measures models. Exposures and outcomes were measured at exam 1 (2000–2002) and exam 5 (2010–2011). Stratified analyses and interaction terms were used to explore effect modification by time, sex, race/ethnicity, and smoking status. RESULTS: In the analytic population, at baseline, ≈46% were men with a median age of 62 (interquartile range, 53–70) years and total flavonoid intakes of 182 (interquartile range, 98–308) mg/d. After multivariable adjustments, participants with the highest (quartile 4) versus lowest (quartile 1) total flavonoid intakes had 26% lower odds of having an ankle-brachial index <1 (odds ratio, 0.74 [95% CI, 0.60–0.92]) and 18% lower odds of having a carotid plaque (odds ratio, 0.82 [95% CI, 0.69–0.99]), averaged over exams 1 and 5. Moderate (quartile 3) to high (quartile 4) intakes of flavonols, flavanol monomers, and anthocyanins were associated with 19% to 34% lower odds of having an ankle-brachial index <1 and 18% to 20% lower odds of having carotid plaque. Participants with the highest intakes of anthocyanins (quartile 4) at baseline had a marginally slower rate of carotid plaque progression than those with moderate intakes (quartiles 2 and 3). There were no significant associations with intima-media thickness or coronary artery calcification. Observed associations did not differ by sex, race/ethnicity, or smoking status. CONCLUSIONS: In this multi-ethnic population, higher dietary flavonoid intakes were associated with lower odds of peripheral and carotid artery atherosclerosis. Increasing intakes of healthy, flavonoid-rich foods may protect against atherosclerosis in the peripheral and carotid arteries.
- 1 November 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (11) , 2347-2359
Associations Between Flavonoid Intake and Subclinical Atherosclerosis: The Multi-Ethnic Study of Atherosclerosis
BACKGROUND: Flavonoids may play a role in mitigating atherosclerotic cardiovascular diseases, with evidence suggesting effects may differ between vascular beds. Studies examining associations with subclinical markers of atherosclerosis between subpopulations with different underlying risks of atherosclerosis are lacking. METHODS: Among 5599 participants from the MESA (Multi-Ethnic Study of Atherosclerosis), associations between dietary flavonoid intakes (estimated from a food frequency questionnaire) and subclinical measures of atherosclerosis (ankle-brachial index, carotid plaques and intima-media thickness, and coronary artery calcification) were examined using repeated measures models. Exposures and outcomes were measured at exam 1 (2000–2002) and exam 5 (2010–2011). Stratified analyses and interaction terms were used to explore effect modification by time, sex, race/ethnicity, and smoking status. RESULTS: In the analytic population, at baseline, ≈46% were men with a median age of 62 (interquartile range, 53–70) years and total flavonoid intakes of 182 (interquartile range, 98–308) mg/d. After multivariable adjustments, participants with the highest (quartile 4) versus lowest (quartile 1) total flavonoid intakes had 26% lower odds of having an ankle-brachial index <1 (odds ratio, 0.74 [95% CI, 0.60–0.92]) and 18% lower odds of having a carotid plaque (odds ratio, 0.82 [95% CI, 0.69–0.99]), averaged over exams 1 and 5. Moderate (quartile 3) to high (quartile 4) intakes of flavonols, flavanol monomers, and anthocyanins were associated with 19% to 34% lower odds of having an ankle-brachial index <1 and 18% to 20% lower odds of having carotid plaque. Participants with the highest intakes of anthocyanins (quartile 4) at baseline had a marginally slower rate of carotid plaque progression than those with moderate intakes (quartiles 2 and 3). There were no significant associations with intima-media thickness or coronary artery calcification. Observed associations did not differ by sex, race/ethnicity, or smoking status. CONCLUSIONS: In this multi-ethnic population, higher dietary flavonoid intakes were associated with lower odds of peripheral and carotid artery atherosclerosis. Increasing intakes of healthy, flavonoid-rich foods may protect against atherosclerosis in the peripheral and carotid arteries.
- Open Access
- 20 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (4) , e032014
Associations of Abdominal Muscle Density and Area and Incident Cardiovascular Disease, Coronary Heart Disease, and Stroke: The Multi‐Ethnic Study of Atherosclerosis
Background: Muscle density is inversely associated with all‐cause mortality, but associations with cardiovascular disease (CVD) risk are not well understood. This study evaluated the association between muscle density and muscle area and incident total CVD, coronary heart disease (CHD), and stroke in diverse men and women. Methods and Results: Adult participants (N=1869) in the Multi‐Ethnic Study of Atherosclerosis Ancillary Body Composition Study underwent computer tomography scans of the L2‐L4 region of the abdomen. Muscle was quantified by density (Hounsfield units) and area in cm 2 . Sex‐stratified Cox proportional hazard models assessed associations between incident total CVD, incident CHD, and incident stroke across sex‐specific percentiles of muscle area and density, which were entered simultaneously into the model. Mean age for men and women at baseline were 64.1 and 65.1 years, respectively, and median follow‐up time was 10.3 years. For men, associations between muscle density and incident CVD were inverse but not significant in fully adjusted models ( P trend=0.15). However, there was an inverse association between density and CHD ( P trend=0.02; HR, 0.26 for 95th versus 10th percentile), and no association with stroke ( P trend=0.78). Conversely, for men, there was a strong positive association between muscle area and incident CVD (HR, 4.19 for 95th versus 10th percentile; P trendP trendP trend=0.67). Associations for women were mostly null. Conclusions: For men, abdominal muscle density is associated with lower CHD risk, whereas greater muscle area is associated with markedly increased risk of CHD.
- 20 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (4) , e032014
Open AccessAssociations of Abdominal Muscle Density and Area and Incident Cardiovascular Disease, Coronary Heart Disease, and Stroke: The Multi‐Ethnic Study of Atherosclerosis
Background: Muscle density is inversely associated with all‐cause mortality, but associations with cardiovascular disease (CVD) risk are not well understood. This study evaluated the association between muscle density and muscle area and incident total CVD, coronary heart disease (CHD), and stroke in diverse men and women. Methods and Results: Adult participants (N=1869) in the Multi‐Ethnic Study of Atherosclerosis Ancillary Body Composition Study underwent computer tomography scans of the L2‐L4 region of the abdomen. Muscle was quantified by density (Hounsfield units) and area in cm 2 . Sex‐stratified Cox proportional hazard models assessed associations between incident total CVD, incident CHD, and incident stroke across sex‐specific percentiles of muscle area and density, which were entered simultaneously into the model. Mean age for men and women at baseline were 64.1 and 65.1 years, respectively, and median follow‐up time was 10.3 years. For men, associations between muscle density and incident CVD were inverse but not significant in fully adjusted models ( P trend=0.15). However, there was an inverse association between density and CHD ( P trend=0.02; HR, 0.26 for 95th versus 10th percentile), and no association with stroke ( P trend=0.78). Conversely, for men, there was a strong positive association between muscle area and incident CVD (HR, 4.19 for 95th versus 10th percentile; P trendP trendP trend=0.67). Associations for women were mostly null. Conclusions: For men, abdominal muscle density is associated with lower CHD risk, whereas greater muscle area is associated with markedly increased risk of CHD.
- Top Cited PapersOpen Access
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e033562
Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis
Background: Effective therapies for reducing cardiovascular disease (CVD) risk in people with elevated lipoprotein(a) are lacking, especially for primary prevention. Because of the potential association of lipoprotein(a) with thrombosis, we evaluated the relationship between aspirin use and CVD events in people with elevated lipoprotein(a). Methods and Results: We used data from the MESA (Multi‐Ethnic Study of Atherosclerosis), a prospective cohort study of individuals free of baseline cardiovascular disease. Due to potential confounding by indication, we matched aspirin users to nonusers using a propensity score based on CVD risk factors. We then evaluated the association between aspirin use and coronary heart disease (CHD) events (CHD death, nonfatal myocardial infarction) stratified by baseline lipoprotein(a) level (threshold of 50 mg/dL) using Cox proportional hazards models with adjustment for CVD risk factors. After propensity matching, the study cohort included 2183 participants, including 1234 (57%) with baseline aspirin use and 423 (19%) with lipoprotein(a) >50 mg/dL. Participants with lipoprotein(a) >50 mg/dL had a higher burden of CVD risk factors, more frequent aspirin use (61.7% versus 55.3%, P =0.02), and higher rate of incident CHD events (13.7% versus 8.9%, P 50 mg/dL and aspirin use had similar CHD risk as those with lipoprotein(a) ≤50 mg/dL regardless of aspirin use. Conclusions: Aspirin use was associated with a significantly lower risk for CHD events in participants with lipoprotein(a) >50 mg/dL without baseline CVD. The results of this observational propensity‐matched study require confirmation in studies with randomization of aspirin use.
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e033562
Top Cited PapersOpen AccessAspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis
Background: Effective therapies for reducing cardiovascular disease (CVD) risk in people with elevated lipoprotein(a) are lacking, especially for primary prevention. Because of the potential association of lipoprotein(a) with thrombosis, we evaluated the relationship between aspirin use and CVD events in people with elevated lipoprotein(a). Methods and Results: We used data from the MESA (Multi‐Ethnic Study of Atherosclerosis), a prospective cohort study of individuals free of baseline cardiovascular disease. Due to potential confounding by indication, we matched aspirin users to nonusers using a propensity score based on CVD risk factors. We then evaluated the association between aspirin use and coronary heart disease (CHD) events (CHD death, nonfatal myocardial infarction) stratified by baseline lipoprotein(a) level (threshold of 50 mg/dL) using Cox proportional hazards models with adjustment for CVD risk factors. After propensity matching, the study cohort included 2183 participants, including 1234 (57%) with baseline aspirin use and 423 (19%) with lipoprotein(a) >50 mg/dL. Participants with lipoprotein(a) >50 mg/dL had a higher burden of CVD risk factors, more frequent aspirin use (61.7% versus 55.3%, P =0.02), and higher rate of incident CHD events (13.7% versus 8.9%, P 50 mg/dL and aspirin use had similar CHD risk as those with lipoprotein(a) ≤50 mg/dL regardless of aspirin use. Conclusions: Aspirin use was associated with a significantly lower risk for CHD events in participants with lipoprotein(a) >50 mg/dL without baseline CVD. The results of this observational propensity‐matched study require confirmation in studies with randomization of aspirin use.
- 17 March 2023
- Published by Taylor & Francis
- p. 57-79
Peripheral Arterial Disease
At least 10 million people in the United States have peripheral artery disease, or PAD, which consists of partial or complete atherosclerotic obstruction of peripheral arteries, typically defined as those arteries supplying the lower extremities. Moreover, as many as 4 million Americans have symptomatic intermittent claudication (IC), which classically consists of pain in the lower extremities, typically induced by exercise and relieved by rest. 1 , 2 Although arteries to sites other than the legs, such as the brain, are also considered peripheral, the term PAD in conventional usage refers expressly to reduced arterial blood flow to the legs. As is true of atherosclerotic disease to vessels supplying the heart, atherosclerotic disease in PAD may be asymptomatic (analogous to silent coronary ischemia), may produce symptoms with exercise (analogous to stable angina), or, in severe cases, may lead to symptoms at rest.
- 17 March 2023
- Published by Taylor & Francis
- p. 57-79
Peripheral Arterial Disease
At least 10 million people in the United States have peripheral artery disease, or PAD, which consists of partial or complete atherosclerotic obstruction of peripheral arteries, typically defined as those arteries supplying the lower extremities. Moreover, as many as 4 million Americans have symptomatic intermittent claudication (IC), which classically consists of pain in the lower extremities, typically induced by exercise and relieved by rest. 1 , 2 Although arteries to sites other than the legs, such as the brain, are also considered peripheral, the term PAD in conventional usage refers expressly to reduced arterial blood flow to the legs. As is true of atherosclerotic disease to vessels supplying the heart, atherosclerotic disease in PAD may be asymptomatic (analogous to silent coronary ischemia), may produce symptoms with exercise (analogous to stable angina), or, in severe cases, may lead to symptoms at rest.
- 1 February 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 16 (2) , 160-169
Coronary Artery Calcium Density and Cardiovascular Events by Volume Level: The MESA
Background: The Agatston coronary artery calcium (CAC) score provides robust cardiovascular disease risk prediction but upweights plaque area by a density factor. Density, however, has been shown to be inversely associated with events. Using CAC volume and density separately improves risk prediction, but it is unclear how to apply this method clinically. We aimed to evaluate the association between CAC density and cardiovascular disease across the spectrum of CAC volume to better understand how to incorporate these metrics into a single score. Methods: We performed an analysis of MESA (Multi-Ethnic Study of Atherosclerosis) participants with detectable CAC to evaluate the association between CAC density and events by level of CAC volume using multivariable Cox regression models. Results: In a cohort of 3316 participants, there was a significant interaction ( P 130 mm 3 was not significant (hazard ratio, 0.82 per unit of density [95% CI, 0.55–1.22]). Conclusions: The lower risk for CHD associated with higher CAC density varied by level of volume, and volume ≤130 mm 3 is a potentially clinically useful cut point. Further study is needed to integrate these findings into a unified CAC scoring method.
- 1 February 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 16 (2) , 160-169
Coronary Artery Calcium Density and Cardiovascular Events by Volume Level: The MESA
Background: The Agatston coronary artery calcium (CAC) score provides robust cardiovascular disease risk prediction but upweights plaque area by a density factor. Density, however, has been shown to be inversely associated with events. Using CAC volume and density separately improves risk prediction, but it is unclear how to apply this method clinically. We aimed to evaluate the association between CAC density and cardiovascular disease across the spectrum of CAC volume to better understand how to incorporate these metrics into a single score. Methods: We performed an analysis of MESA (Multi-Ethnic Study of Atherosclerosis) participants with detectable CAC to evaluate the association between CAC density and events by level of CAC volume using multivariable Cox regression models. Results: In a cohort of 3316 participants, there was a significant interaction ( P 130 mm 3 was not significant (hazard ratio, 0.82 per unit of density [95% CI, 0.55–1.22]). Conclusions: The lower risk for CHD associated with higher CAC density varied by level of volume, and volume ≤130 mm 3 is a potentially clinically useful cut point. Further study is needed to integrate these findings into a unified CAC scoring method.
- Open Access
- 2 August 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (10) , 2328-2335
Higher Arm Versus Lower Arm Systolic Blood Pressure and Cardiovascular Outcomes: a Meta-Analysis of Individual Participant Data From the INTERPRESS-IPD Collaboration
BACKGROUND: Guidelines recommend measuring blood pressure (BP) in both arms, adopting the higher arm readings for diagnosis and management. Data to support this recommendation are lacking. We evaluated associations of higher and lower arm systolic BPs with diagnostic and treatment thresholds, and prognosis in hypertension, using data from the Inter-arm Blood Pressure Difference—Individual Participant Data Collaboration. METHODS: One-stage multivariable Cox regression models, stratified by study, were used to examine associations of higher or lower reading arm BPs with cardiovascular mortality, all-cause mortality, and cardiovascular events, in individual participant data meta-analyses pooled from 23 cohorts. Cardiovascular events were modelled for Framingham and atherosclerotic cardiovascular disease risk scores. Model fit was compared throughout using Akaike information criteria. Proportions reclassified across guideline recommended intervention thresholds were also compared. RESULTS: We analyzed 53 172 participants: mean age 60 years; 48% female. Higher arm BP, compared with lower arm, reclassified 12% of participants at either 130 or 140 mm Hg systolic BP thresholds (both P< 0.001). Higher arm BP models fitted better for all-cause mortality, cardiovascular mortality, and cardiovascular events (all P P <0.001) and reclassified 4.6% and 3.5% of participants respectively to higher risk categories compared with lower arm BPs). CONCLUSIONS: Using BP from higher instead of lower reading arms reclassified 12% of people over thresholds used to diagnose hypertension. All prediction models performed better when using the higher arm BP. Both arms should be measured for accurate diagnosis and management of hypertension. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: CRD42015031227.
- 2 August 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (10) , 2328-2335
Open AccessHigher Arm Versus Lower Arm Systolic Blood Pressure and Cardiovascular Outcomes: a Meta-Analysis of Individual Participant Data From the INTERPRESS-IPD Collaboration
BACKGROUND: Guidelines recommend measuring blood pressure (BP) in both arms, adopting the higher arm readings for diagnosis and management. Data to support this recommendation are lacking. We evaluated associations of higher and lower arm systolic BPs with diagnostic and treatment thresholds, and prognosis in hypertension, using data from the Inter-arm Blood Pressure Difference—Individual Participant Data Collaboration. METHODS: One-stage multivariable Cox regression models, stratified by study, were used to examine associations of higher or lower reading arm BPs with cardiovascular mortality, all-cause mortality, and cardiovascular events, in individual participant data meta-analyses pooled from 23 cohorts. Cardiovascular events were modelled for Framingham and atherosclerotic cardiovascular disease risk scores. Model fit was compared throughout using Akaike information criteria. Proportions reclassified across guideline recommended intervention thresholds were also compared. RESULTS: We analyzed 53 172 participants: mean age 60 years; 48% female. Higher arm BP, compared with lower arm, reclassified 12% of participants at either 130 or 140 mm Hg systolic BP thresholds (both P< 0.001). Higher arm BP models fitted better for all-cause mortality, cardiovascular mortality, and cardiovascular events (all P P <0.001) and reclassified 4.6% and 3.5% of participants respectively to higher risk categories compared with lower arm BPs). CONCLUSIONS: Using BP from higher instead of lower reading arms reclassified 12% of people over thresholds used to diagnose hypertension. All prediction models performed better when using the higher arm BP. Both arms should be measured for accurate diagnosis and management of hypertension. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: CRD42015031227.
- Open Access
- 27 July 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (15) , e025063
Effects of Walking Exercise at a Pace With Versus Without Ischemic Leg Symptoms on Functional Performance Measures in People With Lower Extremity Peripheral Artery Disease: The LITE Randomized Clinical Trial
Background: In people with peripheral artery disease, post hoc analyses of the LITE (Low Intensity Exercise Intervention in Peripheral Artery Disease) randomized trial were conducted to evaluate the effects of walking exercise at a pace inducing ischemic leg symptoms on walking velocity and the Short Physical Performance Battery, compared with walking exercise without ischemic leg symptoms and compared with a nonexercising control group. Methods and Results: Participants with peripheral artery disease were randomized to: home‐based walking exercise that induced ischemic leg symptoms; home‐based walking exercise conducted without ischemic leg symptoms; or a nonexercising control group for 12 months. Outcomes were change of walking velocity over 4 m and change of the Short Physical Performance Battery (0–12, with 12=best) at 6‐ and 12‐month follow‐up. A total of 264 participants (48% women, 61% Black race) were included. Compared with walking exercise without ischemic symptoms, walking exercise that induced ischemic symptoms improved change in usual‐paced walking velocity over 4 m at 6‐month (0.056 m/s [95% CI, 0.019–0.094 m/s]; P P P =0.03), and change in the Short Physical Performance Battery at 12‐month follow‐up (0.821 [95% CI, 0.309–1.334]; P P <0.01). Conclusions: In people with peripheral artery disease, those who walked for exercise at a comfortable pace without ischemic leg symptoms slowed their walking speed during daily life and worsened the Short Physical Performance Battery score, a potentially harmful effect, compared with people who walked for exercise at a pace inducing ischemic leg symptoms. Compared with a control group who did not exercise, home‐based walking exercise at a pace inducing ischemic leg symptoms significantly improved change of walking velocity over 4 m at 6‐month follow‐up, but this benefit did not persist at 12‐month follow‐up. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02538900.
- 27 July 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (15) , e025063
Open AccessEffects of Walking Exercise at a Pace With Versus Without Ischemic Leg Symptoms on Functional Performance Measures in People With Lower Extremity Peripheral Artery Disease: The LITE Randomized Clinical Trial
Background: In people with peripheral artery disease, post hoc analyses of the LITE (Low Intensity Exercise Intervention in Peripheral Artery Disease) randomized trial were conducted to evaluate the effects of walking exercise at a pace inducing ischemic leg symptoms on walking velocity and the Short Physical Performance Battery, compared with walking exercise without ischemic leg symptoms and compared with a nonexercising control group. Methods and Results: Participants with peripheral artery disease were randomized to: home‐based walking exercise that induced ischemic leg symptoms; home‐based walking exercise conducted without ischemic leg symptoms; or a nonexercising control group for 12 months. Outcomes were change of walking velocity over 4 m and change of the Short Physical Performance Battery (0–12, with 12=best) at 6‐ and 12‐month follow‐up. A total of 264 participants (48% women, 61% Black race) were included. Compared with walking exercise without ischemic symptoms, walking exercise that induced ischemic symptoms improved change in usual‐paced walking velocity over 4 m at 6‐month (0.056 m/s [95% CI, 0.019–0.094 m/s]; P P P =0.03), and change in the Short Physical Performance Battery at 12‐month follow‐up (0.821 [95% CI, 0.309–1.334]; P P <0.01). Conclusions: In people with peripheral artery disease, those who walked for exercise at a comfortable pace without ischemic leg symptoms slowed their walking speed during daily life and worsened the Short Physical Performance Battery score, a potentially harmful effect, compared with people who walked for exercise at a pace inducing ischemic leg symptoms. Compared with a control group who did not exercise, home‐based walking exercise at a pace inducing ischemic leg symptoms significantly improved change of walking velocity over 4 m at 6‐month follow‐up, but this benefit did not persist at 12‐month follow‐up. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02538900.
- 1 March 2022
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 15 (3) , 501-503
How Should We Measure and Score Coronary Artery Calcium?
- 1 March 2022
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 15 (3) , 501-503
How Should We Measure and Score Coronary Artery Calcium?